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Methyl-CpG binding proteins: specialized transcriptional
repressors or structural components of chromatin?
Thomas Clouaire and Irina Stancheva*
Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann Building,
Mayfield Road, Edinburgh EH9 3JR, UK
Abstract
DNA methylation is an epigenetic modification that is implicated in transcriptional silencing. It is
becoming increasingly clear that both correct levels and proper interpretation of DNA methylation
are important for normal development and function of many organisms, including humans. In this
review we focus on recent advances in understanding of how proteins that bind to methylated
DNA recognize their binding sites and translate the DNA methylation signal into functional states
of chromatin. Although the function of methyl-CpG binding proteins in transcriptional repression
has been attributed to their cooperation with corepressor complexes, additional roles for these
proteins in chromatin compaction and spatial organization of nuclear domains have also been
proposed. Finally, we provide a brief overview of how methyl-CpG proteins contribute to human
disease processes such as Rett Syndrome and cancer.
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Introduction
Post-synthetic modification of DNA by methylation is found in most living organisms from
bacteria to mammals. In prokaryotes, methylation occurs both on adenine and cytosine
nucleotides and is involved in regulation of DNA replication timing, DNA repair and
defence against invasion by foreign DNA [1]. The genomes of eukaryotes are modified
exclusively at cytosine and in vertebrates only in the context of CpG dinucleotides [2].
Fungi, such as Neurospora crassa, and plants also contain methylated cytosine in non-CpG
context [3,4]. Not all eukaryotes have methylated DNA. Species such as yeast and many
invertebrates, including the nematode C . elegans and the fly D. melanogaster, contain either
no or barely detectable amounts of methylated cytosine in their genomes [2,5].
DNA methylation is introduced into DNA by enzymes of the DNA cytosine
methyltransferases family. In vertebrates, these are represented by DNMT1, DNMT3A and
DNMT3B [6]. DNMT1, the maintenance DNA methyltransferase, works most efficiently on
hemi-methylated DNA and functions to restore symmetrically methylated cytosine on
daughter DNA strands generated during replication [7,8]. DNMT3 enzymes, also referred to
as de novo methyltransferases, can work on fully unmodified DNA and are essential for
establishment of DNA methylation patterns during embryogenesis [9].
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Most genomes with high levels of DNA methylation are depleted of CpGs due to the
frequent deamination of methyl-cytosine into thymidine. This generates mCpG:TpG
mismatches which, if unrepaired, are further stabilized by DNA replication [2,10]. The
remaining CpGs are unevenly distributed throughout the genome. Most gene promoters
(~70% in mammals) are imbedded in an unmethylated stretches of DNA with high CpG
density, also known as CpG islands [2,11,12]. How the CpG islands are maintained in an
unmethylated state and what protects them from the action of DNA methyltransferases is
currently unclear. Nevertheless, these sequences are not intrinsically unmethylatable since
some of them acquire DNA methylation in differentiated cells and can be found aberrantly
methylated in cancers [13,14]. The lack of methylation at CpG islands and heavily
methylated coding and intergenic regions generate patterns of DNA methylation that are
heritably maintained in somatic cell lineages [2].
Biological functions of DNA methylation have been intensively studied over several
decades. It is now well established that DNA methylation generally associates with silent
chromatin which is inhibitory to transcriptional initiation [11,15]. Important processes such
as monoallelic expression of imprinted genes in plants and placental animals, X-
chromosome inactivation in mammals and suppression of transposable elements in complex
genomes include DNA methylation as part of more complex regulatory functions [16,17].
Given that most of the gene promoters are methylation-free, the question of whether DNA
methylation is essential for regulation of gene expression on a global scale has been a
subject of debate [2,16,18]. Nevertheless, mice with disrupted alleles of Dnmt1 or double
null for Dnmt3a and Dnmt3b die early in embryogenesis and show inappropriate expression
of large number of genes [9,19,20]. Xenopus laevis embryos depleted of DNMT1 initiate
zygotic transcription 2-3 cell cycles earlier than it normally occurs at the midblastula
transition and display aberrant expression of developmentally decisive genes [21,22].
Therefore, at least in vertebrates, DNA methylation plays a conserved role in maintaining
stable patterns of gene expression. Additional evidence from plants and the primitive
chordate C. intestinalis shows that methylated cytosines are enriched within the coding
regions of genes and may regulate transcriptional elongation [23,24]. It is worth mentioning
that a role for DNA methylation in suppressing “transcriptional noise” in large genomes, i.e.
initiation of spurious transcription from cryptic promoters within coding regions of genes or
non-coding DNA, has been proposed and still requires more detailed investigation [25,26].
There are two models of how DNA methylation exerts its repressive effect on transcription.
In the first model, CpG methylation alters binding sites of transcription factors and directly
interferes with gene activation [11]. Examples validating this model include E2F, CREB and
c-myc [27-29]. In the second model, methylated cytosines serve as docking sites for proteins
that specifically recognize and bind to methylated CpGs and repress transcription indirectly
via recruitment of corepressors that modify chromatin [11,15]. In this review we focus on
the methyl-CpG binding proteins and how they translate DNA methylation patterns into
functional states of chromatin.
Families of methyl-CpG binding proteins
Currently two major families of methyl-CpG binding proteins are known in vertebrates:
MBDs and Kaiso-like proteins. In addition, recent studies indicate that SRA domain
proteins, characterized in some detail in plants, have the ability to bind methylated DNA in
non-CpG context.
MBD family proteins
Ironically, the first methyl-CpG binding protein, MeCP2, was discovered by accident by
Adrian Bird and co-workers, who at the time were attempting to identify factors that bind to
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unmethylated DNA and would function to protect CpG islands from DNA methylation.
Instead, protein factors, initially named MeCP1 and MeCP2 that bind specifically to
methylated DNA were detected [30,31]. MeCP2 was purified first and represents a 53 kDa
protein containing a N-terminal methyl-CpG binding domain (MBD) and a C-terminal
transcriptional repression domain (TRD) [32,33]. Mammalian EST database homology
searches for sequences encoding a conserved MBD domain led to the identification of four
additional proteins currently known as MBD1, MBD2, MBD3 and MBD4 [34] (Figure1). Of
those, MBD2 and MBD3 are closely related to each other outside the MBD domain (77%
identity) and are likely to represent the ancestral MBD family founders since a homologous
MBD2/3 like protein is present in invertebrates, including Drosophila where low levels of
DNA methylation are detectable only in early development [5,35]. All MBD proteins,
except MBD3, specifically recognize and bind to methylated DNA in vitro and in vivo [34].
Mammalian MBD3, unlike its amphibian homologue, harbours a critical mutation in the
MBD domain and does not bind to methylated DNA [15,34]. The MBD family proteins,
including MeCP2, are highly conserved in all vertebrates [36]. Interestingly, at least 12
MBD proteins have been identified in the plant Arabidopsis thaliana. Of these AtMBD5,
AtMBD6 and AtMBD7 have been shown to bind methylated DNA in vitro [37].
Kaiso family proteins
Kaiso, the founder protein of Kaiso-like family, was independently discovered in two
different laboratories as a DNA binding factor involved in non-canonical Wnt signalling and
as a protein that binds to methylated DNA [38,39]. Unlike the MBD family members, Kaiso
and the two recently identified Kaiso-like proteins ZBTB4 and ZBTB38 contain a conserved
POZ domain involved in protein-protein interactions and three C2H2 zinc finger motifs, two
of which are essential for binding to methylated DNA [40] (Figure1). Unmethylated
sequences recognized by Kaiso with high affinity have also been reported [41] raising the
possibility that in some circumstances Kaiso and Kaiso-like proteins may bind to
nonmethylated DNA and to methylated DNA in others.
SRA domain proteins
Recent reports suggest that another protein fold, the SRA (or YNG) domain could interpret
DNA methylation [42-44]. SRA domain-containing proteins fall in two distinct families.
The first one is characterised by association of the SRA domain with PHD and RING finger
domains. At least 5 members of this family exist in A. thaliana including the product of the
recently cloned vim1 gene [42]. So far described mammalian homologues include the Np95
protein, the closely related Np97 (or NIRF) and ICBP90 [42,44]. Recent studies suggest that
Np95 plays a critical role in epigentic inheritance of DNA methylation [45,46]. The second
family of SRA domain proteins is plant- specific, without obvious mammalian counterparts,
and includes members of the SUVH family of SET domain histone methyltransferases in A.
thaliana [43]. Interestingly, the SRA domain seems more versatile than the MBD domain in
recognizing methylated DNA as in vitro it binds to methyl-cytosine at CpG, CpNpG and
even at the asymmetric CpNpN sites, with a marked preference for mCpNpG [42,43].
In the rest of this review we will focus in more detail on the MBD and in part the Kaiso-like
proteins in mammalian cells.
DNA binding properties of methyl-CpG binding proteins
The molecular functions of methyl-CpG binding proteins rely on their ability to recognize
and bind methylated DNA. As this property is central to understanding their roles in vivo,
we will review the current progress in this area in more detail.
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Deletion analyses have identified the minimal region of MeCP2 responsible for the
interaction with methylated CpGs [32]. Further comparison with other MBD proteins
defined the MBD domain as a protein motif of about 75 amino acids [34,47]. Since the
“classical” MBD was described, proteins containing MBD-like domain, including ESET/
SETDB1 and TIP5, have also been identified in different species. However, as in the case of
TIP5 protein, the MBD-like domains are predicted not to form specific interactions with
methylated DNA and therefore may serve other functions. A unifying name of TAM domain
(TIP5, ARBP, MBD) is now used to unify both canonical MBD and MBD-like domains
[47]. MBD-like domains proteins are not the subject of this review.
Sequence comparison of all human MBD family proteins show the presence of 16 strictly
conserved amino acids within the MBD domain. MBD3, which does not bind to methylated
DNA, lacks four of these conserved residues [34]. Pairwise comparison reveals the presence
of two subclasses, with the MBD domains of MBD4 and MeCP2 being more closely related
to each others, while those of MBD1, MBD2 and even MBD3 forming a separate subgroup.
Solution structures of MBD domains of human MeCP2 and MBD1 have been determined by
NMR revealing a similar α/β sandwich fold composed of four β-strands and an α-helix
[48,49] (Figure2A and B). Detailed information on how the MBD fold binds symmetrically
methylated CpG was derived from the NMR structure of the MBD domain of MBD1 in
complex with methylated DNA [50] (Figure2C and D).
MBD proteins interact with methylated DNA in the major groove, where the two methyl
groups from the mCpG point towards the exterior of the double helix (Figure 2C). Several
residues from the L1 loop, connecting the β2 and β3 strands, and the α helix respectively
make several contacts with the sugar/phosphate backbone on each strand of the DNA
molecule (Figure 2D). Four conserved residues (R22, Y34, R44, S45) in MBD1 are involved
in recognizing the methyl-CpGs via a complex set of interactions. It appears that each side
chain interacts with DNA in a somehow bivalent way, where the polar moiety of each of
these residues contacts C or G base, while their hydrophobic regions stack around the
methyl groups. Such of bivalent contacts from each important amino acid side chain may
explain why both the CpG dinucleotide and the two methyl groups are strictly required for
efficient recognition by the MBD. Subtle variations in this network might abolish binding.
MBD3 for example has only three of the four conserved residues with Tyrosine (Y) to
Phenylalanine (F) substitution at the equivalent position of Y34. The loss of a single
hydroxyl group renders MBD3 incapable of binding to methylated DNA [34,51]. This
particular arrangement of critical amino acids is likely to explain the high selectivity
observed in vitro towards methylated DNA versus either hemimethylated or unmethylated
CpGs. The structural data also confirm that one MBD domain can only accommodate one
symmetrically methylated CpG as the MBD domain binds DNA as a monomer [32,48].
However, this does not exclude the presence of potential homo or heterodimerisation
interfaces on MBD proteins, even if MeCP2 appear to be mostly monomeric in solution
[52]. The only case that complicates this picture is MBD4, whose MBD domain seems
capable of interacting preferentially with mCpG:TpG mismatches arising from deamination
of methyl-cytosine and even with hemimethylated DNA [53,54]. The structural information
available so far does not explain why MBD4, whose MBD domain is related to MeCP2
more than any other, would display an altered DNA binding specificity. However, it seems
that cytosine methylation and even the MBD itself can be dispensable for MBD4 G:T
mismatch-specific thymine glycosylase activity [55].
About 70 to 80% of CpG are methylated in mammalian genomes, creating a relatively high
number of potential binding sites for MBD proteins [2]. Then what determines their pattern
of occupancy at these sites? One possible model would be that each MBD protein randomly
occupies any available methylated CpG (Figure 3A). In this scenario, the relative abundance
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of each MBD protein within a cell, together with the methylation density will dictate the
occupancy of individual methylated sites. This random behaviour would imply high
redundancy and is the principal argument to explain the relatively mild phenotypes of
MBD1, MBD2 and Kaiso null mice [56-58]. In another model, one can envisage that other
factors may influence the distribution of MBD proteins within a cell nucleus, making it non-
uniform and non-random, with each MBD protein occupying unique sites in the genome
(Figure 3B). This model would predict that a subset of genes would be affected by the loss
of one MBD protein but not other. Examples of genes missexpressed in the absence of
specific MBD proteins are becoming more abundant and the phenotypes of MBD deficient
mice, although subtle, are markedly different [56,58-61].
In support of the second model, a recent study demonstrates that in primary human
fibroblasts, MBD1, MBD2 and MeCP2 do not share binding sites in vivo, at least at the
number of genomic sequences examined [62]. Morpholino-mediated depletion of MeCP2
and MBD2 suggested the existence of a mechanism dictating preference of MeCP2 but not
MBD2 for a subset of methylated sites in vivo [62]. Whether this selective binding is
retained in cancer cells, which tend to accumulate aberrant DNA methylation patterns, is
unclear [63]. Specific targeting of MBD proteins, observed in primary cells, may be
achieved via interactions with binding partners (see below) including other DNA binding
activities which may facilitate targeting of MBDs to chromatin or DNA at specific loci.
Experimental evidence for recruitment via partner proteins is currently missing. Another
possibility, which has been validated to some extent, is that the various members of the
MBD family display different DNA binding specificity, meaning that they recognize and
bind to more complex sequences than a single methylated CpG.
Recent in vitro experiment showed that, unlike MBD2, MeCP2 requires a run of four or
more A/T base pairs adjacent to methylated CpG for high affinity binding [62]. Furthermore
[A/T]≥4 runs are present at MeCP2 target sequences identified in vivo [62]. These findings
constitute the first example where the enhanced binding specificity towards a particular set
of methylated sequences allows discriminative binding site occupancy of an MBD protein.
Whether this is the case for other MBD proteins remains to be determined. However, as
MeCP2 and MBD1 contain additional DNA binding domains, it is possible that a single
methylated CpG is not sufficient to support high affinity binding of an MBD protein to
DNA. Early studies on MeCP2 detected a potential second DNA binding activity
independent of the MBD domain and sequence analyses identified the presence of two AT-
hooks [31,62,64] (Figure1). The AT-hook motif is capable of interacting with the minor
groove of AT rich DNA and has been characterized in high mobility group proteins such as
HMGA1 [65]. However, the AT hooks are frequently present in conjunction with other
functional DNA or chromatin binding domains [66], and in the case of MeCP2 their
functionality remains to be determined. Surprisingly, the AT hooks are not required for
selective binding of MeCP2 to CpG followed by [A/T]≥4 run [62]. However, these motifs
may interact with other stretches of A/T-rich DNA in cis or trans. Additionally, a role of the
C-terminus of MeCP2 in helping binding to DNA, matrix attachment regions and
nucleosome has also been reported [67-70]. Whether multiple DNA and chromatin binding
interfaces play a role in MeCP2 function requires further studies.
On the other hand, MBD1 protein carries a second functional DNA binding motif separate
from the MBD. Depending on the isoform, MBD1 can have two or three zinc finger motifs
defined by 8 conserved cysteines, the CxxC zinc finger [71,72]. However, each copy is not
strictly equivalent to one another, as they display primary sequence differences that would
alter their biochemical properties. The most C terminal zinc finger (usually referred as
CxxC3), which we will consider as a canonical CxxC motif, is also present in various other
proteins, including DNMT1, CpG binding protein CGBP, H3K4 histone methylase MLL
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and H3K36 histone demethylases of the Jumonji family JHDM1A and JHDM1B [71,73,74].
This canonical version of the CxxC zinc finger has been shown to bind non methylated
CpGs in vitro in the case of MBD1, MLL CGBP and JHDM1B [71,74-76]. The two other
CxxC motifs of MBD1 lack a conserved glutamine residue and a KFGG motif, characteristic
of all DNA binding CxxC zinc fingers, and as a consequence are unable to bind DNA [71].
The role of these divergent CxxC zinc fingers is unclear but they might be involved in
protein-protein interactions [61].
In reporter gene assays, MBD1 represses transcription from CpG rich unmethylated
promoters in a CxxC3 domain-dependant manner [71,72]. This suggests that this domain
could be as efficient as the MBD for targeting MBD1 to DNA in vivo and therefore, MBD1
may play a role in silencing certain unmethylated CpG island promoters. However, the
CxxC3 domain by itself does not provide enough sequence specificity to discriminate
between different CpG islands, which are defined by their high CpG content. A
mechanism(s) that would account for the specific targeting of MBD1, and other CxxC
containing protein, to specific DNA loci remains to be uncovered. An attractive hypothesis
would be that MBD1 requires each of its two DNA binding domains for efficient binding at
specific loci in vivo. As each domain interacts with a very short sequence (2 nucleotides)
compared to classical DNA binding transcription factors, one can speculate that the use of
two separate DNA binding domains might enhance the specificity for particular sequences
in vivo. Another possibility is that, similar to MeCP2 which requires a methylated CpG
followed by an [A/T]≥4 run, each DNA binding domain of MBD1 recognizes a more
complex sequence than currently known. Whether MBD1 binds DNA through an
independent use of its two DNA binding domains, or they collaborate with each other to
target efficiently MBD1 to specific loci will be an intriguing question to answer.
It might appear surprising that a methyl-CpG binding protein carries a domain that allows it
to bind unmethylated CpGs. However, this ability to interact with methylated and
unmethylated DNA is not a unique feature of MBD1. The identification of Kaiso showed
that the MBD domain is not the only protein fold able to recognize DNA methylation, as
Kaiso and the Kaiso-like proteins ZBTB4 and ZBTB38 use a set of C2H2 zinc fingers to
bind methylated DNA [39,40]. Early studies suggested that Kaiso requires at least two
mCpGs for efficient binding, while ZBTB4 and ZBTB38 seem to interact with a single
mCpG [39,40]. In vitro studies also show that Kaiso interacts specifically with unmethylated
consensus sequence, the Kaiso Binding Site (KBS:TCCTGCNA), which is present at
promoters of Wnt target genes [77,78]. Interestingly, only zinc fingers 2 and 3 of Kaiso are
necessary and sufficient for binding to either type of sequences in vitro [41]. The ability to
bind unmethylated DNA is shared by ZBTB4, but surprisingly not by ZBTB38. High
resolution structural information may help to explain how the zinc-fingers of Kaiso and
Kaiso-like proteins interact with methylated and unmethylated DNA. Such structural studies
may facilitate the design of specific point mutations which would allow uncoupling of
mCpG and KBS binding activities and clear cut discrimination between the functions of
Kaiso and ZBTB4 that rely on their interaction with either methylated or unmethylated
DNA.
In summary, several lines of evidence suggest that methyl-CpG binding proteins recognize
more complex sequences than a single methylated CpG, thus favouring a gene or locus
specific role for each member of the MBD and Kaiso-like families. As MBD proteins are
widely expressed in different tissues and constitute relatively abundant chromosomal
proteins, it has been suggested that they may also exert functions unrelated to recognition of
methylated DNA. Although binding of MBD proteins to other nucleic acids such as RNA
and cruciform DNA structures in vitro has been reported [79,80], evidence in vivo for the
most part firmly supports the function of MBD proteins in reading DNA methylation
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patterns at specific loci. One likely explanation for the existence of two (and maybe more)
families of divergent methyl-CpG binding proteins, with members that display different
sequence specificity towards methylated DNA, could be the evolutionary adaptation of pre-
existing nucleic acid binding motifs for binding to methylated DNA.
Establishment of silenced chromatin by methyl-CpG binding proteins
Early studies have demonstrated that DNA methylation has no major impact on gene
expression until the DNA template is assembled into chromatin [81,82]. Once the MBD
proteins were discovered and shown to function as methylation-dependent transcriptional
repressors, the work in several laboratories has focused on identification of co-repressor
complexes associated with these proteins. Currently, it is established that MBD proteins
cooperate with histone deacetylases and histone methylase activities that modify chromatin
and prevent productive initiation of transcription [15] (Figure 4).
Protein complexes containing MeCP2 and MBD2 have been purified by biochemical
fractionation and found to contain class I histone deacetylase activities HDAC1 and HDAC2
[33,83,84]. MeCP2 was co-purified with Sin3A/HDAC2 complex from Xenopus oocyte
extract and a number of studies have shown than the interactions of MeCP2 with Sin3A and
HDAC2 are conserved in mammalian cells and are essential for MeCP2-mediated repression
[33,83]. A number of other proteins directly or indirectly interacting with MeCP2 have been
found including DNMT1, CoREST, NCoR/SMRT, c-SKI, histone H3 lysine 9 methylase
activity, RNA splicing factors and chromatin remodelling activities such as ATRX and
Brahma (Brm1)-related SWI/SNF complex [85-92]. Nevertheless, the composition of a well
defined MeCP2 co-repressor complex that would be present in all cell types or tissues
remains elusive. Purification of MeCP2 from mammalian sources, including brain where
this protein is most abundant, has produced conflicting results, ranging from complete lack
of stable association of MeCP2 with either Sin3A, or any other proteins in nuclear extracts
[52,93], to the identification of high molecular weight MeCP2 containing complexes
[89,91,94]. Some of these discrepancies could be explained by the use of different
biochemical methods that may vary in sensitivity of detection of MeCP2-associated
proteins. It is also possible that most of the interactions of MeCP2 with partner proteins are
either relatively unstable or cell type- and/or locus- specific [94]. In addition, these findings
raise the possibility that DNA-bound MeCP2 may interact with partner proteins differently
compared to the unbound form of MeCP2, which behaves as an unusually elongated
monomeric molecule in solution [52]. Perhaps affinity tagging of the endogenous MeCP2
protein and tandem purification of the MeCP2 containing complexes from a variety of
tissues may provide some interesting insights.
MBD2 and MBD3 co-purify with a large protein complex known as NuRD (Nucleosome
Remodelling and Histone Deacetylation) which contains chromatin remodelling ATPase
Mi-2, HDAC1 and HDAC2 histone deacetylases as well as other proteins [84,95]. The
NuRD complex exists in several forms and may or may not contain MBD proteins. Initially,
it was suggested that MBD2 and MBD3 together associate with NuRD [84,96,97], but
recent affinity tag purifications of MBD2 and MBD3 complexes from mammalian cells
showed that NuRD associates either with MBD2 or MBD3 but never with both proteins
[98]. These different MBD complexes have probably no or very little functional overlap
since MBD3 null mice die early during embryogenesis while MBD2-deficient animals are
viable and fertile [56]. As MBD3 does not bind to methylated DNA, these findings indicate
that only a proportion of NuRD complexes would be recruited to methylated DNA and
participate in methylation-dependent transcriptional repression. It appears that association
with ATP-dependent chromatin remodelling activities is a common feature of MeCP2- and
MBD2-associated protein complexes. Although MeCP2 and MBD2 are likely to be
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responsible for the initial recruitment of these complexes to chromatin assembled on
methylated DNA, studies in vitro and in vivo suggest that chromatin remodelling activities
further facilitate binding of MBD proteins to methylated sites that are not readily accessible
on nucleosomal templates and by doing so stimulate MBD-mediated gene repression
[89,99].
MBD1 protein in most assays behaves as a histone deacetylation-independent transcriptional
repressor [100]. At least two histone H3 lysine 9 (H3K9) methylase activities SETDB1 and
SUV39H have been found associated with MBD1 as well as the heterochromatin protein
HP1 [61,101]. In addition the C-terminus of MBD1 binds a SETDB1 co-factor AM/MCAF
which stimulates SETDB1 activity to allow more efficient di- and trimethylation of H3K9
[102,103]. Furthermore, it was shown that during S-phase of the cell cycle MBD1/SETDB1
complex can be displaced from methylated DNA by progressing replication forks to allow
the formation of a transient complex with p150 subunit of chromatin assembly factor CAF-1
[61]. As a result of this interaction, the MBD1-bound SETDB1 methylates H3K9 of the H3/
H4 dimers associated with CAF-1. Thus the S-phase specific MBD1 complex facilitates
post-replicative maintenance of the repressive H3K9 chromatin modification on methylated
daughter DNA strands [61]. This mechanism provides a plausible explanation of how
silenced chromatin can be heritably transmitted through DNA replication and cell division in
synchrony with DNA methylation. The function of MBD1 in transcriptional repression and
maintenance of H3K9 methylation is negatively regulated by conjugation of SUMO1 [104].
Two E3 SUMO-ligases PIAS1 and PIAS3 sumoylate MBD1 in human cells and compete
against SETDB1 for interaction with MBD1. SETDB1 can bind MBD1-SUMO1 in vitro but
not in vivo suggesting that there could be a specific binding partner(s) for sumoylated
MBD1, which disrupt the formation of the MBD1/SETDB1 complex [104]. Identification of
factors that bind MBD1-SUMO1 but not MBD1 will be essential for the mechanistic
understanding of how the function of MBD1 might be regulated in response to physiological
stimuli. Intriguingly, conjugation of SUMO2/3 to MBD1 has also been reported and, unlike
SUMO1, seems to stimulate transcriptional repression by MBD1 [105]. Therefore it is
possible that these two modifications recruit different binding partners to MBD1. Given that
a number of proteins were found to associate with MBD1, biochemical purification of
MBD1 complex(es) may help to determine whether MBD1 stably associates with a set of
co-repressor proteins or, like MeCP2, could cooperate with many different nuclear factors.
Similar to MBDs, Kaiso-like proteins function as HDAC-dependent transcriptional
repressors. From HeLa cell nuclear extracts, Kaiso co-purifies with NCoR (Nuclear receptor
Co-Repressor) complex containing histone deacetylase HDAC3 and this association is
required for silencing of methylated MTA2 promoter [106]. Depletion of Kaiso in Xenopus
embryos results in derepression of methylated genes before the midblastula transition [107].
However, Xenopus Kaiso is also involved in a non-canonical Wnt pathway where its
function is controlled through an association with p120-catenin and is essential for
regulation of target genes in a methylation-independent manner [77,78]. Complexes
containing Kaiso-like proteins have not yet been purified but ZBTB38 protein was shown to
interact with several histone deacetylases activities and co-repressor CtBP [108].
Taken together, methyl-CpG binding proteins represent an important class of chromosomal
proteins which associate with multiple protein partners to modify surrounding chromatin and
silence transcription, providing a functional link between DNA methylation and chromatin
remodelling and modification.
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MBD proteins and chromatin architecture
Independently from the establishment of transcriptionally inactive chromatin via cooperation
with corepressor proteins, a more direct role of MBD proteins in organization of higher
order chromatin structure has also been proposed. Earlier studies have shown that MeCP2
forms discrete complexes with nucleosomes assembled on methylated DNA, can displace
histone H1 from pre-assembled chromatin and in addition is able to interact with the
nucleosome core via its C-terminus [67,109]. More recent studies have reported that purified
recombinant MeCP2 when added to nucleosomal arrays in vitro causes chromatin
compaction, which has been attributed to additional interactions between MeCP2 and DNA
or chromatin in cis or trans via a domain(s) different from the MBD [68,69].
In vivo, in mouse cells, MeCP2 as well as other MBD and Kaiso-like proteins localize to
condensed pericentric heterochromatin regions known as chromocenters (Figure 5A-D).
These chromatin domains are also enriched in histone H3 trimethylated at lysine 9 and
heterochromatin proteins HP1α and HP1β [110,111]. During myogenic differentiation of
mouse C2C12 cells the pericentric heterochromatin domains undergo reorganization and
cluster into smaller number of larger chromocenters [112]. These events are accompanied by
an increase in methylation of major satellite DNA and accumulation of MeCP2 and MBD2
proteins in the nuclei of terminally differentiated muscle cells (myotubes). Interestingly,
overexpression of MeCP2 and MBD2 in C2C12 myoblasts in the absence of differentiation
also induces aggregation of chromocenters indicating that these proteins may be directly
involved in reorganization of heterochromatin architecture [112]. As overexpression of
MBD domain of MeCP2 is sufficient to cause fusion of chromocenters, these events are
unlikely to involve co-repressor HDAC complexes or other proteins interacting with the C-
terminal region of MeCP2. The mechanism by which MBD proteins induce aggregation of
chromocenters is unclear although it has been suggested that it may be caused by
oligomerization of MBD proteins and formation of DNA-MBD-MBD-DNA structures or
multiple interactions between MBD protein and DNA as mentioned above [69]. Given that
neither MeCP2 nor MBD2 nor their MBD domains form dimers or oligomers in vitro, the
second interpretation seems more plausible. However, the chromocenters in mouse cells do
not undergo decompaction or visible reorganization in the absence of MeCP2 or MBD2, and
the differentiation of muscle tissues in MeCP2 and MBD2 null animals seems to proceed
normally [56,113]. Therefore the functional significance of MBD proteins localizing to
pericentric heterochromatin domains is yet to be established. Intriguingly, a recent study
reports aggregation of chromocenters in mouse ES cells null for Dnmt3a/3b where major
satellite DNA is mostly unmethylated [114]. It is possible that mouse cells respond to any
drastic changes in components of constitutive heterochromatin by dynamic rearrangement of
chromocenters.
In human cells, where the pericentric heterochromatin does not cluster into specific domains
that can be visualized by DNA-staining dyes, each MBD protein displays distinct
localization (Figure 5E-H). In most human cell types MeCP2 is diffusely distributed
throughout the nucleus, while MBD2 and MBD1 form several bright foci on a weaker
background of diffuse distribution throughout the nucleus [101,104]. The nature and
functional significance of MBD1 and MBD2 foci are currently unclear. In the case of
MBD1, these structures seem to be enriched in heterochromatin-specific histone
modifications and proteins such H3K9 methylases SUV39H and SETDB1, and HP1 [105].
It would be of interest to determine whether genes silenced by DNA methylation are
recruited to MBD foci. Additional studies by chromatin conformation capture (3C) analyzes
may provide some essential information regarding these structures.
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The role of MBD proteins in human disease
It is becoming clear that mutations in proteins involved in establishment of DNA
methylation patterns as well as DNA methylation effectors, such as MBD proteins, lead to
complex human disease phenotypes. For example, mutations in the de novo DNA
methyltransferase DNMT3B result in immunodeficiency/centromeric instability/facial
anomalies (ICF) syndrome and mutations in the MeCP2 gene, located on the X-
chromosome, cause one of the most common forms of mental retardation in females known
as Rett syndrome [115,116]. In addition, genome-wide loss of DNA methylation and
aberrant methylation of CpG island promoters of genes controlling restricted cellular growth
are considered important epigenetic hallmarks of cancer [13]. Despite the functional
importance of MBD proteins in recognizing DNA methylation, the means by which MBD
proteins mediate the physiological functions of DNA methylation in normal tissues remain
for the most part unclear. However, genetic analyses of mice null for specific methyl-CpG
binding proteins have allowed their role in disease processes to be investigated in detail.
Rett syndrome (RTT) is a late onset (6 months after birth) severe autism spectrum disorder
that affects 1 in 10,000 girls and is caused almost exclusively by mutations in the MeCP2
gene [116]. Due to the random X chromosome inactivation, RTT patients are usually mosaic
in the expression of the wild type and the mutant copy of the gene and show abnormal
neuronal morphology but not neuronal death [117]. Conditional deletions and neuron-
specific expression of MeCP2 in mice have shown that Rett phenotype is caused by MeCP2
deficiency in postmitotic mature neurons [118,119]. Mice null for MeCP2 protein have been
generated and shown to recapitulate the most essential features of the human Rett Syndrome
[113,119]. MeCP2-deficient males, unlike humans, survive postnatally and develop the
symptoms of the disease at ~6 weeks and die after ~11 weeks. MeCP2-deficient females
have milder phenotype and therefore survive longer and are fertile [113,119]. Recent reports
have challenged previous views that Rett Syndrome is a neurodevelopmental disorder. Thus
re-expression of the MeCP2 gene in Mecp2lox-Stop/y mice with progressing disease
phenotype is sufficient to reverse the neurological symptoms of RTT [120]. These
experiments clearly suggest that MeCP2-deficient neurons develop functionally normal and
are not irreversibly damaged by the absence of MeCP2. Important molecular cues,
presumably DNA methylation, that allow MeCP2 to function in mature neurons are
established appropriately in the absence of MeCP2. These experiments convincingly
demonstrate the principle of reversibility of Rett syndrome and are consistent with the
hypothesis that MeCP2 is required to stabilize and maintain the state of mature neurons.
Nevertheless, it is yet unclear whether MeCP2 function in the brain involves maintenance of
specific chromatin conformation or regulation of a few key genes. Target genes for MeCP2-
mediated repression are still sparse and microarray studies have not detected major changes
in gene expression in the brain of MeCP2-null animals [121-123]. Perhaps, detailed studies
of MeCP2 function in specifically in differentiated neurons will help to determine why this
protein is so crucial for their integrity.
Substantial evidence in vivo suggests that MBD proteins contribute to transcriptional
repression at methylated gene promoters, especially in tumours where many promoter-
associated CpG islands are aberrantly methylated [13,36,63]. In mice that carry
heterozygous mutant allele of the Apc gene (Apc+/min), a spontaneous inactivation of the
wild type allele often occurs in the intestine and leads to development of adenomas and
subsequent death of these animals at an age of about 180 days [124]. However, Apc+/min
mice lacking Mbd2 or Kaiso proteins show reduced incidence of intestinal tumours and
significantly improved survival compared to Apc+/min littermates with wild type Mbd2 or
Kaiso alleles [36,57]. Antisense oligonucleotide knock down of MBD2 in xenographs has
also been shown to suppress tumour growth validating MBD2 as a potential target for anti-
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cancer therapy [125]. It will be interesting to determine whether mice null for MBD1 protein
are resistant to development of tumours when crossed onto Apc+/min background. On the
other hand, Mbd4-deficient Apc+/min mice display accelerated tumour formation consistent
with the proposed role of MBD4 in suppression of CpG mutability and tumorigenesis in
vivo [126]. Taken together, these genetic studies clearly indicate that methyl-CpG binding
proteins contribute to development of cancer phenotypes in mouse models.
Studies in human cancers have identified a number of aberrantly methylated promoters of
tumour suppressor genes that are bound by MBD proteins. Candidate gene approach and
genome-wide studies using CpG-island microarrays showed that a significant proportion of
methylated promoters are bound by a single MBD protein, most often MBD2 [63,127].
However, unlike primary human cells, about half of all methylated promoters seem to be
occupied by more than one MBD protein [63]. Whether cooperation between MBD proteins
is required for stable silencing of densely methylated CpG islands in cancer cells is yet to be
established.
Conclusions and future directions
Considerable amount of work over the last years have contributed to understanding of the
role of DNA methylation in mammalian development and human disease. Nevertheless,
many questions remain unresolved, including most fundamental ones of how the patterns of
DNA methylation are established in vertebrate genomes and what causes dramatic changes
of these patterns in pathological states such as cancer. Studies on proteins that bind
methylated DNA have demonstrated that these proteins act as important effectors of DNA
methylation and are involved in establishment and maintenance of transcriptionally silenced
chromatin and, perhaps, higher order chromatin structure. Recent data have provided
evidence that methyl-CpG binding proteins do not share binding sites in vivo and can
recognize methylated DNA within specific sequence context. Perhaps, in some cases the
binding selectivity could be attributed to structural properties of the domain that interacts
with methylated DNA. In others, cooperation between the methyl-CpG binding domain and
other DNA binding motifs could be essential for discrimination between different
methylated loci and targeting distinct subsets of genes. Further work in vitro and in vivo,
structural studies of these proteins in complex with appropriate DNA sequences and
genome-wide analyses of their binding profiles will provide additional essential information
and will facilitate more detailed mechanistic understanding of their complex functions.
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Figure 1. Families of methyl-CpG binding proteins
MBD family proteins share a conserved MBD domain, which is required for binding to
methylated DNA. MBD3 carries a mutation (shown in orange) in the MBD domain and does
not bind to methylated CpGs. MeCP2 has two AT-hook motifs (ATh) which potentially
could bind AT-rich DNA. These motifs are not required for high affinity binding to
sequences containing a methylated CpG followed by an [A/T]≥4 run. MBD1 is characterized
by two (or three in some isoforms) CxxC-type zinc fingers. The third CxxC motif (orange)
binds unmethylated CpGs.
TRD indicates transcriptional repression domains mapped by functional and deletion
analyses. GD indicates Glycosylase domain of MBD4 which is involved in excision of
CG:TG mismatches. (GR)11 motif of MBD2 is a stretch of Glycine and Arginine residues
that can be methylated by PRMT5 protein methylase [98]. (E)12 is a glutamate-rich domain.
Kaiso family of proteins is characterized by three homologous C2H2 zinc finger motifs that
are required for binding to methylated and in some instances unmethylated DNA. In
addition, all proteins of this family carry a BTB/POZ domain likely to be involved in either
homo- or heterodimerization or protein-protein interactions. ZBTB4 and ZBTB38 have
additional three and seven, respectively, zinc finger motifs.
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Figure 2. Interaction of the MBD domain with methylated DNA
A. Schematic representation of the solution structure of MBD domain of MeCP2 [49]. The
beta sheets (β), an alpha helix (α1q) and a long loop 1 (L1) are indicated. B. Solution
structure of MBD domain of MBD1 [48]. C. MBD domain of MBD1 bound to DNA in the
major groove where the methyl-groups (yellow) of methylated cytosines (magenta) are
exposed towards the exterior of the double helix [50]. Residues (purple) from the two beta
sheets as well as L1 and shorter loot connecting β4 with α1 are involved in interactions with
the methyl-groups and the cytosine bases. G bases of the CpG pairs are colored in green. D.
Top view of the MBD domain of MBD1 in contact with a pair of symmetrically methylated
CpG (the top pair is indicated with brighter colours). The side chains (purple) of Valine 20
and Arginine 22 are involved in recognizing the first (top) methyl-group while those of
Tyrosine 34, Arginine 44 and Serine 45 contact the second methyl-group. The figures were
generated from published structures by Cn3D software.
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Figure 3. Models of how MBD proteins recognize methylated DNA
A. The “team” model indicates a non-discriminative binding of MBD proteins to any
accessible methylated CpG. Thus most binding sites will be potentially shared and the
overall pattern of occupancy will be governed by the concentration of each MBD protein. B.
The “team” model would predict redundancy of MBD proteins where the repression of any
methylated gene, for example gene A, could be achieved by any methyl-CpG binding
protein. C. The “solo” model implies specificity of binding where some MBD proteins
discriminate between binding sites either by recognition of bases adjacent to the mCpG or
other nearby DNA motifs. Therefore most of the binding sites will not be shared.
D. The “solo” model would imply that each MBD protein by occupying a distinct set of
binding sites would regulate a specific subset of genes.
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Figure 4. Complexes of MBDs with co-repressor proteins
A. MeCP2 co-immunoprecipitates with Sin3A/HDAC1 complex from most cell types.
HDAC1 removes acetyl groups (*Ac) from histone tails and is responsible for MeCP2-
mediated repression. Histone tails free of acetylation can be modified by histone methylase
activity associated with MeCP2 to generate heterochromatin. B. MBD1 interacts with
SETDB1 histone methylase and SETDB1 co-factor AM/MCAF1. SETDB1 methylates K9
of histone H3 tail to generate silenced chromatin. H3K9me3 is further recognized by
heterochromatin protein HP1. C. MBD2 participates in a large protein complex known as
NuRD, which includes HDAC1 and HDAC2, which, similar to MeCP2 associated complex,
deacetylates histone tails to generate transcriptionally silent chromatin. Methylated CpGs are
shown as red dots.
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Figure 5. Nuclear localization of MBD proteins in mouse and human cells
A, C, D. Mouse 3T3 cells transfected with plasmids expressing human GFP-tagged MBD
proteins display identical localization that coincides with the heterochromatic chromocenters
B. The chromocenters in mouse cells (the same cells as in A) as visualized by staining with
DAPI. E, G and H. GFP-tagged MBD proteins transfected into human HeLa cells show
localization specific to each protein. F. The DNA of same cells as shown in E was also
stained with DAPI. Note that pericentric heterochromatin does not form chromocenters in
human cells.
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